Overview

Evaluation of the Neoadjuvant Treatment With Oxaliplatin -UFT- Radiotherapy in Rectal Cancer

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
Primary objective: - To evaluate the rate of responses to neoadjuvant therapy + radiotherapy Secondary objective: - tolerability (toxicity) and time to progression
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sanofi
Treatments:
Oxaliplatin